CN114958775B - 一种稻瘟酰胺人工抗原、单克隆抗体、杂交瘤细胞株及其应用 - Google Patents
一种稻瘟酰胺人工抗原、单克隆抗体、杂交瘤细胞株及其应用 Download PDFInfo
- Publication number
- CN114958775B CN114958775B CN202210726155.8A CN202210726155A CN114958775B CN 114958775 B CN114958775 B CN 114958775B CN 202210726155 A CN202210726155 A CN 202210726155A CN 114958775 B CN114958775 B CN 114958775B
- Authority
- CN
- China
- Prior art keywords
- blastamide
- monoclonal antibody
- hybridoma cell
- cell line
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000004408 hybridoma Anatomy 0.000 title claims abstract description 30
- 235000007164 Oryza sativa Nutrition 0.000 title claims abstract description 15
- 235000009566 rice Nutrition 0.000 title claims abstract description 15
- 240000007594 Oryza sativa Species 0.000 title claims 2
- 239000000427 antigen Substances 0.000 title abstract description 19
- 102000036639 antigens Human genes 0.000 title abstract description 19
- 108091007433 antigens Proteins 0.000 title abstract description 19
- 150000001408 amides Chemical class 0.000 title abstract description 4
- 238000001514 detection method Methods 0.000 claims abstract description 19
- 239000000203 mixture Substances 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 238000004321 preservation Methods 0.000 claims description 4
- 230000003248 secreting effect Effects 0.000 claims description 3
- 244000005700 microbiome Species 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 25
- 241000209094 Oryza Species 0.000 abstract description 13
- 238000002965 ELISA Methods 0.000 abstract description 12
- 230000035945 sensitivity Effects 0.000 abstract description 10
- 239000002671 adjuvant Substances 0.000 abstract description 8
- 238000012216 screening Methods 0.000 abstract description 7
- 238000011725 BALB/c mouse Methods 0.000 abstract description 5
- 210000004988 splenocyte Anatomy 0.000 abstract description 5
- 238000007920 subcutaneous administration Methods 0.000 abstract description 5
- 230000004927 fusion Effects 0.000 abstract description 4
- IUOKJNROJISWRO-UHFFFAOYSA-N N-(2-cyano-3-methylbutan-2-yl)-2-(2,4-dichlorophenoxy)propanamide Chemical compound CC(C)C(C)(C#N)NC(=O)C(C)OC1=CC=C(Cl)C=C1Cl IUOKJNROJISWRO-UHFFFAOYSA-N 0.000 abstract description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract description 3
- 238000002347 injection Methods 0.000 abstract description 3
- 239000007924 injection Substances 0.000 abstract description 3
- 201000000050 myeloid neoplasm Diseases 0.000 abstract description 3
- 230000002860 competitive effect Effects 0.000 abstract description 2
- 239000001963 growth medium Substances 0.000 abstract description 2
- 102000014914 Carrier Proteins Human genes 0.000 abstract 1
- 108010078791 Carrier Proteins Proteins 0.000 abstract 1
- 210000004754 hybrid cell Anatomy 0.000 abstract 1
- 230000003053 immunization Effects 0.000 description 30
- 238000002649 immunization Methods 0.000 description 30
- 239000000243 solution Substances 0.000 description 26
- 238000000034 method Methods 0.000 description 22
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- 239000012980 RPMI-1640 medium Substances 0.000 description 11
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 206010003445 Ascites Diseases 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 230000007910 cell fusion Effects 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 239000000417 fungicide Substances 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 239000005662 Paraffin oil Substances 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 3
- 239000012154 double-distilled water Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000003113 dilution method Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 101000609762 Gallus gallus Ovalbumin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 229930182844 L-isoleucine Natural products 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 241001344131 Magnaporthe grisea Species 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 241000233679 Peronosporaceae Species 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- HHGZUQPEIHGQST-UHFFFAOYSA-N [2-[(2-azaniumyl-2-carboxyethyl)disulfanyl]-1-carboxyethyl]azanium;dichloride Chemical compound Cl.Cl.OC(=O)C(N)CSSCC(N)C(O)=O HHGZUQPEIHGQST-UHFFFAOYSA-N 0.000 description 1
- MUUGCDGGIVCSDT-UHFFFAOYSA-N [NH4+].[NH4+].[O-]S([O-])(=O)=O.CCCCCCCC(O)=O Chemical compound [NH4+].[NH4+].[O-]S([O-])(=O)=O.CCCCCCCC(O)=O MUUGCDGGIVCSDT-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- -1 amino, carboxyl Chemical group 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000021329 brown rice Nutrition 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 238000007499 fusion processing Methods 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- UOKZUTXLHRTLFH-UHFFFAOYSA-N o-phenylhydroxylamine Chemical compound NOC1=CC=CC=C1 UOKZUTXLHRTLFH-UHFFFAOYSA-N 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 125000003396 thiol group Chemical class [H]S* 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2430/00—Assays, e.g. immunoassays or enzyme assays, involving synthetic organic compounds as analytes
- G01N2430/10—Insecticides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
本发明涉及一种稻瘟酰胺人工抗原、单克隆抗体、杂交瘤细胞株及其应用。本发明合成了一种稻瘟酰胺半抗原,半抗原与载体蛋白偶联合成完全抗原,随后与等量弗氏佐剂混合乳化,通过颈背部皮下多点注射免疫BALB/c小鼠。将高滴度和高灵敏度小鼠的脾细胞与小鼠骨髓瘤细胞进行融合,采用选择培养基,筛选出两种细胞融合后的杂交细胞;再经过间接竞争酶联免疫法筛选细胞,并进行多次亚克隆,最终得到一株杂交瘤细胞。此细胞株分泌的单克隆抗体,对稻瘟酰胺具有较好的检测灵敏度(IC50值为1.33ng/mL)与特异性,可以用于稻瘟酰胺的残留检测。
Description
技术领域
本发明涉及食品安全免疫检测领域,尤其涉及一种稻瘟酰胺人工抗原、单克隆抗体、杂交瘤细胞株及其应用。
背景技术
稻瘟酰胺的英文通用名为:Fenoxanil,化学名称:N-(1-腈基-1,2-二甲基丙基)-2-(2,4-二氯苯氧基)丙酰胺。稻瘟酰胺属于苯氧酰胺类杀菌剂,是新内吸性杀菌剂,有杰出的治疗、渗透作用和抑制孢子形成等特性,并系统地分布在非原生质体,可单用也可与保护性杀菌剂混用。其作用机理为黑色素生物合成抑制剂,主要是抑制小柱孢酮脱氢酶的活性,从而抑制稻瘟病菌黑色素形成。稻瘟酰胺具有良好内吸性和卓越的特效性,施药后对新展开的叶片也有很好效果,对苯酰胺类杀菌剂的抗性品系和敏感品系均有活性。对葡萄霜霉病,马铃薯和番茄晚疫病防效较好。
目前,稻瘟酰胺检测方法主要为仪器检测,常用的有气相色谱法、液相色谱法和气相色谱-质谱法。尽管这些基于色谱的方法具有很高的灵敏度和特异性,存在一些缺点,例如需要彻底的样品净化,高溶剂消耗,昂贵的设备以及熟练的技术人员。因此,需要一种快速,简便的检测稻瘟酰胺残留物的方法。
酶联免疫吸附试验(ELISA)是一种极为高效、灵敏、快速的检测方法,检测时对样本的前处理简单、纯化步骤少、分析容量大、检测成本低而且操作简便,适用于大量样本的现场快速检测,因此在药物残留分析中得到了广泛应用。而使用酶联免疫法检测稻瘟酰胺的前提是得到对稻瘟酰胺具有高特异性和高灵敏度的单克隆抗体,因此,找到一种制备对稻瘟酰胺具有高特异性和高灵敏度的单克隆抗体的方法十分关键。发明人尝试通过杂交瘤细胞制备稻瘟酰胺单克隆抗体,但在制备能分泌稻瘟酰胺单克隆抗体的杂交瘤细胞株的过程中,如何制备稻瘟酰胺半抗原和完全抗原和如何使小鼠产生强免疫效应,还需进一步的研究;如何使得制备出的杂交瘤细胞株能够成功分泌出稻瘟酰胺单克隆抗体,还需进一步的研究;如何使得分泌出的稻瘟酰胺单克隆抗体特异性强、灵敏度高,也还需进一步的研究。
发明内容
为解决上述技术问题,本发明提供了一种稻瘟酰胺人工抗原、单克隆抗体、杂交瘤细胞株及其应用。此杂交瘤细胞株分泌的稻瘟酰胺单克隆抗体对稻瘟酰胺具有较好的检测灵敏度(IC50值为1.33ng/mL),可以用于建立稻瘟酰胺的免疫学检测方法,检测食品中稻瘟酰胺的残留。
本发明的技术方案如下:
本发明的第一个目的在于提供一种分泌稻瘟酰胺单克隆抗体的杂交瘤细胞株,所述杂交瘤细胞株已于2022年03月03日,保藏于中国微生物菌种保藏管理委员会普通微生物中心,保藏编号为CGMCC No.45117,保藏地址为北京市朝阳区北辰西路1号院3号。
本发明的第二个目的在于提供所述的杂交瘤细胞株的制备方法,包括以下步骤:
(1)制备稻瘟酰胺半抗原及稻瘟酰胺完全抗原,将获得的稻瘟酰胺完全抗原与弗氏佐剂进行乳化得到免疫原1,稻瘟酰胺完全抗原与不完全弗氏佐剂乳化得到免疫原2;
(2)将步骤(1)所得免疫原1对动物进行首次皮下免疫,并用免疫原2进行加强免疫;
(3)对经过步骤(2)免疫过程的动物进行采血,筛选出血清中稻瘟酰胺抗体灵敏度高的动物;
(4)对步骤(3)筛选出的动物进行冲刺免疫,冲刺免疫采用不含弗氏佐剂的稻瘟酰胺完全抗原;
(5)将步骤(4)冲刺免疫后的动物的脾细胞和骨髓瘤细胞进行融合,得到所述分泌稻瘟酰胺单克隆抗体的杂交瘤细胞株。
在本发明的一个实施例中,步骤(1)中,所述稻瘟酰胺半抗原的分子式为:
在本发明的一个实施例中,步骤(1)中,所述稻瘟酰胺完全抗原的分子式为:
在本发明的一个实施例中,所述稻瘟酰胺完全抗原通过以下方法制备得到:将稻瘟酰胺半抗原、N-羟基琥珀酰亚胺及1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐溶解于有机溶剂中,搅拌反应,得到活化的稻瘟酰胺半抗原溶液,将稻瘟酰胺半抗原溶液加入到钥孔血蓝蛋白用碳酸盐缓冲溶液中进行反应,得到所述稻瘟酰胺完全抗原。
在本发明的一种实施方式中,稻瘟酰胺半抗原、N-羟基琥珀酰亚胺及1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐的摩尔比为1:1-5:1-5。
在本发明的一种实施方式中,所述偶联用蛋白选自牛血清白蛋白、鸡卵清白蛋白、人血清白蛋白、钥孔血蓝蛋白或人工合成的多聚赖氨酸。
在本发明的一种实施方式中,步骤(2)、(4)中,所述首次皮下免疫与加强免疫之间间隔一个月,加强免疫之间间隔21天,加强免疫与冲刺免疫之间间隔18-21天。
在本发明的一种实施方式中,步骤(2)、(4)中,所述首次皮下免疫的剂量为100μg/只,加强免疫剂量为50μg/只,冲刺免疫剂量为25μg/只。
在本发明的一种实施方式中,步骤(3)中,所述免疫过程,包含1次首次皮下免疫、至少4次加强免疫和1次冲刺免疫。
在本发明的一种实施方式中,步骤(3)中,所述采血的时间为第3次免疫过程结束后第7天进行采血。
在本发明的一种实施方式中,步骤(5)中,将冲刺免疫后的BALB/c小鼠的脾细胞和骨髓瘤细胞进行融合,融合后的细胞通过HAT培养基筛选培养,利用间接ELISA检测阳性细胞孔,并进一步利用间接竞争ELISA法测定阳性细胞孔的抑制效果,通过有限稀释法对有最好抑制的阳性细胞孔进行亚克隆,最终筛选出获得能分泌高灵敏度稻瘟酰胺单克隆抗体的杂交瘤细胞株;
在本发明的一种实施方式中,步骤(5)中,所述细胞融合是在冲刺免疫结束3天后进行。
在本发明的一种实施方式中,步骤(5)中,所述细胞融合是通过聚乙二醇(PEG4000)法进行的。
在本发明的一种实施方式中,步骤(5)中,所述培养基为RPMI-1640培养基。
在本发明的一种实施方式中,步骤(5)中,所述亚克隆次数为4次。
本发明的第三个目的在于提供所述杂交瘤细胞株在制备稻瘟酰胺单克隆抗体中的应用。
在本发明的一种实施方式中,一种稻瘟酰胺单克隆抗体的制备方法为取动物,腹腔注射石蜡油,再腹腔注射保藏编号为CGMCC No.45117的杂交瘤细胞株,注射后收集腹水,将腹水纯化,将获得的单克隆抗体低温保存。
在本发明的一种实施方式中,所述方法为取8-10周龄BALB/c小鼠,每只小鼠腹腔注射石蜡油1mL,7天后每只小鼠腹腔注射1×106个细胞/mL保藏编号为CGMCC No.45117的杂交瘤细胞株,从第7天开始收集腹水,将腹水通过辛酸-硫酸铵法纯化,获得的单克隆抗体置于-20℃保存。
本发明的第四个目的在于提供一种稻瘟酰胺单克隆抗体,所述稻瘟酰胺单克隆抗体是由所述杂交瘤细胞株分泌获得。
本发明的第五个目的在于提供所述的杂交瘤细胞株、所述的稻瘟酰胺单克隆在检测稻瘟酰胺中的应用。
本发明的第六个目的在于提供一种组合物,所述组合物包含所述的杂交瘤细胞株和/或所述的稻瘟酰胺单克隆抗体。
本发明的第七个目的在于提供所述的组合物在检测稻瘟酰胺中的应用。
本发明所述杂交瘤细胞株分类命名为单克隆细胞株。
本发明的技术方案具有以下优点:
本发明获得的稻瘟酰胺单克隆抗体,对稻瘟酰胺有较好的检测灵敏度(IC50值为1.33ng/mL);本发明获得的稻瘟酰胺单克隆抗体细胞株可以用于免疫分析检测。
附图说明
为了使本发明的内容更容易被清楚的理解,下面根据本发明的具体实施例并结合附图,对本发明作进一步详细的说明,其中
图1为本发明稻瘟酰胺单克隆抗体对稻瘟酰胺的抑制标准曲线。
具体实施方式
下面结合附图和具体实施例对本发明作进一步说明,以使本领域的技术人员可以更好地理解本发明并能予以实施,但所举实施例不作为对本发明的限定。
下述实施例中涉及的培养基如下:
RPMI-1640培养基(mg/L):L-精氨酸290、L-门冬酰胺50、L-门冬氨酸20、L-胱氨酸二盐酸盐65.15、L-谷氨酸20、甘氨酸10、L-组氨酸15、L-羟脯氨酸20、L-异亮氨酸50、L-亮氨酸50、L-赖氨酸盐酸盐40、L-甲硫氨酸15、L-苯丙氨酸15、L-脯氨酸20、L-丝氨酸30、L-苏氨酸20、L-色氨酸5、L-酪氨酸23.19、L-缬氨酸20、对氨基苯甲酸1、硝酸钙100、无水硫酸镁48.84、无水磷酸二氢钠676.13、氯化钾400、氯化钠6000、葡萄糖2000、还原谷胱甘肽1、酚红5、L-谷氨酰胺300、生物素0.2、D-泛酸钙0.25、叶酸1、i-肌醇35、烟酰胺1、氯化胆碱3、盐酸吡哆醇1、核黄素0.2、盐酸硫胺素1、维生素B12 0.005、碳酸氢钠2000。
下述实施例中涉及的试剂如下:
碳酸盐缓冲液(CBS):称取Na2CO31.59 g,NaHCO32.93 g,分别溶于少量双蒸水后混合,加双蒸水至约800mL混匀,调pH值至9.6,加双蒸水定容至1000mL,4℃贮存备用。
磷酸盐缓冲液(PBS):8.00g NaCl,0.2g KCl,0.2g KH2PO4,2.9g Na2HPO4·12H2O,溶于800mL纯水中,用NaOH或HCl调pH到7.2-7.4,定容至1000mL。
PBST:含0.05%吐温20的PBS。
抗体稀释液:含0.1%明胶的PBS。
TMB显色液:A液:Na2HPO4.12H2O 18.43g,柠檬酸9.33g,纯水定容至1000mL;B液:60mg TMB溶于100mL乙二醇中。A、B液按5:1混合即为TMB显色液,使用时再进行混合。
下述实施例中涉及的检测方法如下:
稻瘟酰胺抑制率检测方法:通过棋盘试验选择ic-ELISA中最合适的抗原和抗体浓度。用碳酸盐缓冲液(CBS)将抗原稀释至0.01,0.03,0.1和0.3μg/mL,并用抗体稀释液将抗体稀释至0.03,0.1,0.3和1μg/mL。选择最佳工作点后,将稻瘟酰胺标准品稀释为8个浓度(0,0.034,0.103,0.309,0.926,2.778,8.333和25ng/mL),按照ic-ELISA操作步骤,最后用OriginPro 8.5做图(结果如图1所示),获得稻瘟酰胺标准抑制曲线,计算IC50。
实施例1:稻瘟酰胺半抗原的合成
由于稻瘟酰胺小分子不具有免疫原性,不能刺激小鼠产生免疫应答,进而产生抗体,因此需通过蛋白连接技术将稻瘟酰胺偶联到蛋白上,使其获得免疫原性;蛋白偶联技术中常用的活泼基团有氨基,羧基,羟基,巯基等,鉴于稻瘟酰胺分子结构式中不含有这些活泼基团,因此对稻瘟酰胺进行衍生。
将200mg稻瘟酰胺溶解在200μL丙酮中,搅拌下逐滴加入装有3mL氢氧化钠(0.1M)的圆底烧瓶中,80℃水浴反应72h,反应液冷却至室温,冰浴下用0.1M盐酸溶液将反应液pH调至3,用5mL乙酸乙酯萃取三次,收集有机相加入无水硫酸钠,上清氮气吹干,即得稻瘟酰胺半抗原。
实施例2:稻瘟酰胺完全抗原的合成
称取19mg稻瘟酰胺半抗原,9.3mg N-羟基琥珀酰亚胺(NHS),溶解于200μLN,N-二甲基甲酰胺(DMF)中,室温搅拌反应10min;再称取15.4mg 1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐(EDC),加入到稻瘟酰胺半抗原溶液中,室温搅拌反应6-8h,进行活化。取6mg钥孔血蓝蛋白(KLH),加入到3mL0.01 M碳酸盐缓冲液(CBS),充分溶解,将活化的半抗原缓慢加入到溶解了KLH的稀释液中,室温搅拌过夜。然后用0.01M PBS溶液透析,除去未反应的小分子物质,得到较为纯净的稻瘟酰胺完全抗原,并通过紫外吸收扫描方法进行鉴定。
实施例3:稻瘟酰胺包被原的合成
将7.2mg稻瘟酰胺半抗原、3.6mg N-羟基琥珀酰亚胺(NHS)溶解于200μL无水N,N-二甲基甲酰胺(DMF)中,室温搅拌反应10min;将6mg 1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐(EDC)溶解于上述溶液中,室温搅拌进行反应6-8h,得到半抗原活化液;将6mg牛血清白蛋白溶解于碳酸盐缓冲液(CBS)中;将半抗原活化液缓慢加入到蛋白稀释液中,室温搅拌过夜。然后,用0.01M PBS溶液透析反应液,除去未反应的小分子物质,得到稻瘟酰胺包被原。
实施例4:分泌稻瘟酰胺单克隆抗体的杂交瘤细胞株的制备
1、动物免疫的获得
将稻瘟酰胺完全抗原与等量弗氏佐剂混合乳化后,对BALB/c小鼠进行颈背部皮下多点注射免疫(冲刺免疫除外);首次免疫用完全弗氏佐剂,剂量为100μg/只;多次加强免疫用不完全弗氏佐剂且剂量减半即为50μg/只;冲刺免疫不用佐剂,直接用生理盐水稀释后腹腔注射,剂量再减半即为25μg/只;首次免疫与第二次加强免疫之间间隔一个月,多次加强免疫之间间隔21天,冲刺免疫与最后一次加强免疫之间间隔18-21天;通过间接竞争酶联免疫法(ic-ELISA)观测小鼠免疫效果即检测小鼠血清的效价和抑制。
2、细胞融合
在冲刺免疫三天后,按照常规PEG(聚乙二醇,分子量为4000)方法进行细胞融合,具体步骤如下:
a、颈椎脱臼法处死小鼠后,立即放入75%酒精中消毒,浸泡5min左右,无菌操作取出小鼠的脾脏,用注射器的胶头适度研磨并通过200目细胞筛网得到脾细胞悬液,收集,离心(1200rpm,8min),用RPMI-1640培养基洗涤脾细胞三次,最后一次离心后,将脾细胞稀释到一定体积,计数,备用;
b、收集SP2/0细胞:融合前7-10天,将SP2/0瘤细胞用含10%FBS(胎牛血清)RPMI-1640培养基在5%CO2培养箱中进行扩增,融合前要求SP2/0瘤细胞数量达到1~4×107,保证融合前SP2/0瘤细胞处于对数生长期,融合时,收集瘤细胞,悬浮于RPMI-1640基础培养液中,进行细胞计数;
c、融合过程7min:第1min,将1mL的PEG 4000由慢到快滴加到细胞中;第2min,静置;第3min和第4min,在1min内滴加1mL RPMI-1640培养基;第5min和第6min,在1min内滴加2mL RPMI-1640培养基;第7min,每10s滴加1mL的RPMI-1640培养基。除第2min,其他时间不断晃动溶液。然后37℃温浴5min;离心(800rpm,8min),弃上清,重悬入含20%胎牛血清,2%的50×HAT的RPMI-1640筛选培养液中,按照200μL/孔加到96孔细胞板,置于37℃,5%CO2培养箱中培养。
3、细胞筛选与细胞株建立
在细胞融合后的第3天对融合细胞进行RPMI-1640筛选培养液半换液,第5天进行用含20%胎牛血清,1%的100×HT的RPMI-1640过渡培养液进行全换液,在第7天取细胞上清进行筛选。
筛选分两步:第一步先用ic-ELISA法筛选出阳性细胞孔,第二步选用稻瘟酰胺为标准品,用ic-ELISA法对阳性细胞进行抑制效果测定。
选择对稻瘟酰胺标准品有较好抑制的细胞孔,采用有限稀释法进行亚克隆,七天后用同样的方法进行检测。
按上述方法进行至少三次亚克隆,最终获得稻瘟酰胺单克隆抗体细胞株。
实施例5:稻瘟酰胺单克隆抗体的制备与鉴定
取8-10周龄BALB/c小鼠,每只小鼠腹腔注射无菌石蜡油1mL;7天后每只小鼠腹腔注射1×106稻瘟酰胺杂交瘤细胞,从第七天开始收集腹水,将腹水通过辛酸-饱和硫酸铵法进行抗体纯化。
在偏酸条件下,正辛酸可以沉淀腹水中除IgG免疫球蛋白外的其他杂蛋白,然后离心,弃沉淀;再用等量饱和度的硫酸铵溶液沉淀IgG型的单克隆抗体,离心,弃上清,用0.01M的PBS溶液(pH 7.4)溶解后,透析脱盐,最终得到纯化后的单克隆抗体置于-20℃保存。
使用间接竞争ELISA,测得稻瘟酰胺单克隆抗体的IC50值为1.33ng/mL,说明对稻瘟酰胺有很好的灵敏度,可用于稻瘟酰胺免疫分析检测。
实施例6:稻瘟酰胺单克隆抗体的应用
将杂交瘤细胞株通过体内腹水制备的单克隆抗体应用于稻瘟酰胺的ELISA添加回收试验,具体步骤如下:
(1)将用碳酸盐缓冲液(CBS)稀释好的浓度为0.1μg/mL的包被原包被96孔酶标板,每孔100μL,37℃烘2h后,用PBST洗液洗板三次,每次每孔200μL,每次3min,拍干;
(2)用含0.2%明胶的CBS进行封闭,每孔200μL,37℃烘2h,用PBST洗液洗板三次,每次每孔200μL,每次3min,拍干;
(3)用磷酸盐缓冲液(PBS)分别配置0,0.034,0.103,0.309,0.926,2.778,8.333和25ng/mL的稻瘟酰胺标准溶液,将标准溶液以及待检测样品提取液,分别加入到已经封闭好的酶标板中,每孔50μL,每个样品重复3个孔,再每孔加入50μL稀释至0.1μg/mL的稻瘟酰胺单克隆抗体,37℃反应30min后,洗板拍干;
(4)每孔加入100μL用含0.1%明胶的PBS以1:3000稀释的HRP标记的羊抗鼠IgG二抗,37℃反应30min后,洗板拍干;
(5)每孔加入100μL的TMB显色液,37℃显色15min后,每孔加入50μL 2M的H2SO4终止液,450nm测吸光值;
(6)添加回收及样品前处理:
选择糙米为检测样品。
待测样品经粉碎后过20目的标准筛网,分别称取三份样品,每份20g,向样品中分别添加5ppb、10ppb、50ppb的稻瘟酰胺标准品(根据抗体线性范围及IC50设定添加浓度),加10mL水涡旋混匀,静置30min,抽滤。试样中再加入50mL丙酮,于电动振荡器上震荡30min,用快速定性滤纸过滤于烧杯中,残渣再用30mL丙酮按上法提取一次,用30mL丙酮分两次洗涤残渣,洗液并入烧杯,于50℃水浴上浓缩近干,用5mL的10%丙酮PBS溶液复溶(即稀释了五倍以减少样品基质的影响)。
采用间接竞争ELISA进行添加回收试验,其回收率分别为92.6%,107.3%,90.5%。
显然,上述实施例仅仅是为清楚地说明所作的举例,并非对实施方式的限定。对于所属领域的普通技术人员来说,在上述说明的基础上还可以做出其它不同形式变化或变动。这里无需也无法对所有的实施方式予以穷举。而由此所引申出的显而易见的变化或变动仍处于本发明创造的保护范围之中。
Claims (6)
1.一种分泌稻瘟酰胺单克隆抗体的杂交瘤细胞株,其特征在于,所述杂交瘤细胞株已于2022年03月03日,保藏于中国微生物菌种保藏管理委员会普通微生物中心,保藏编号为CGMCC No.45117,保藏地址为北京市朝阳区北辰西路1号院3号。
2.权利要求1中所述杂交瘤细胞株在制备稻瘟酰胺单克隆抗体中的应用。
3.一种稻瘟酰胺单克隆抗体,其特征在于,所述稻瘟酰胺单克隆抗体是由权利要求1中所述杂交瘤细胞株分泌获得。
4.如权利要求1所述的杂交瘤细胞株或权利要求3所述的稻瘟酰胺单克隆抗体在制备检测稻瘟酰胺的制剂中的应用。
5.一种组合物,其特征在于,所述组合物包含权利要求1所述的杂交瘤细胞株和/或权利要求3中所述的稻瘟酰胺单克隆抗体。
6.如权利要求5所述的组合物在制备检测稻瘟酰胺的制剂中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210726155.8A CN114958775B (zh) | 2022-06-24 | 2022-06-24 | 一种稻瘟酰胺人工抗原、单克隆抗体、杂交瘤细胞株及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210726155.8A CN114958775B (zh) | 2022-06-24 | 2022-06-24 | 一种稻瘟酰胺人工抗原、单克隆抗体、杂交瘤细胞株及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114958775A CN114958775A (zh) | 2022-08-30 |
CN114958775B true CN114958775B (zh) | 2023-04-07 |
Family
ID=82965912
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210726155.8A Active CN114958775B (zh) | 2022-06-24 | 2022-06-24 | 一种稻瘟酰胺人工抗原、单克隆抗体、杂交瘤细胞株及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114958775B (zh) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114563513A (zh) * | 2022-03-08 | 2022-05-31 | 上海市农业科学院 | 一种检测低毒类农药含量的方法 |
-
2022
- 2022-06-24 CN CN202210726155.8A patent/CN114958775B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN114958775A (zh) | 2022-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113684187B (zh) | 一种分泌氟啶草酮单克隆抗体的杂交瘤细胞株及其制备方法和应用 | |
CN108998422A (zh) | 一种分泌噻虫嗪单克隆抗体的杂交瘤细胞株及其应用 | |
CN114317451B (zh) | 一株分泌敌草隆单克隆抗体的杂交瘤细胞株及其制备方法和应用 | |
CN110607283A (zh) | 一株分泌三氯杀螨醇单克隆抗体的杂交瘤细胞株cbc及其应用 | |
CN116376847B (zh) | 一株分泌噁唑菌酮单克隆抗体的杂交瘤细胞株及其应用 | |
CN114107219B (zh) | 一株分泌杀虫脒单克隆抗体的杂交瘤细胞株及其应用 | |
CN113621583B (zh) | 一株分泌烯酰吗啉单克隆抗体的杂交瘤细胞株及其应用 | |
CN110819597A (zh) | 一株分泌腐霉利单克隆抗体的杂交瘤细胞株及其应用 | |
CN113717950B (zh) | 一株分泌戊菌唑单克隆抗体的杂交瘤细胞株及其应用 | |
CN114958775B (zh) | 一种稻瘟酰胺人工抗原、单克隆抗体、杂交瘤细胞株及其应用 | |
CN108866009B (zh) | 一株甲霜灵单克隆抗体杂交瘤细胞株及其应用 | |
CN113151188B (zh) | 一株分泌苯海拉明单克隆抗体的杂交瘤细胞株及其应用 | |
CN110724192A (zh) | 一株分泌蛇形菌素单克隆抗体的杂交瘤细胞株及其应用 | |
CN114181911B (zh) | 一种分泌螺内酯及其代谢物单克隆抗体的杂交瘤细胞株及其应用 | |
CN105754954A (zh) | 一株吡虫啉单克隆抗体杂交瘤细胞株yh5及其应用 | |
CN110343669A (zh) | 一株分泌抗三氯苯达唑单克隆抗体的杂交瘤细胞株dnc及其应用 | |
CN114752568A (zh) | 呋塞米单克隆抗体、杂交瘤细胞株及应用 | |
CN114774366B (zh) | 一株分泌氟吡呋喃酮单克隆抗体的杂交瘤细胞株及其应用 | |
CN115261330B (zh) | 一种粉唑醇人工抗原、单克隆抗体、杂交瘤细胞株及其应用 | |
CN114908060B (zh) | 一株分泌苯酰菌胺单克隆抗体的杂交瘤细胞株及其应用 | |
CN114480295B (zh) | 一株分泌抗仲丁灵单克隆抗体杂交瘤细胞株及其应用 | |
CN114277000B (zh) | 一株分泌稻瘟灵单克隆抗体的杂交瘤细胞株及其应用 | |
CN113502273B (zh) | 一株分泌氟啶胺单克隆抗体的杂交瘤细胞株及其应用 | |
CN110747173A (zh) | 一株分泌三卡因单克隆抗体的杂交瘤细胞株hot及其应用 | |
CN115109757B (zh) | 一株分泌新生霉素单克隆抗体的杂交瘤细胞株及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |